Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

  • Weekly insulin helps patients with type 2 diabetes achieve similar blood sugar control to daily insulin

    A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results, which will be presented at ENDO 2021, the Endocrine Society’s annual meeting, compared an investigational drug called basal insulin Fc (BIF) with insulin degludec, a commercially available long-lasting daily insulin, in patients with type 2 diabetes.

  • As more are vaccinated, it makes economic sense to gradually open the economy : Study

    A University of New Mexico research team conducted a data analysis that has found that as a larger portion of the population gets vaccinated against COVID-19, it becomes economically advantageous to start relaxing social distancing measures and open businesses. Francesco Sorrentino, associate professor of mechanical engineering, is lead author of “Data-driven Optimized Control of the COVID-19 Epidemics,” published March 22 in Scientific Reports.

  • Breast cancer detection through Deep Learning, developed by India

    Cancer is incurable, but if the disease is detected in time, effective treatment can be done. Scientists have developed a new technique, which can be helpful in timely detection of breast cancer. Researchers say this technique will help save the lives of women battling breast cancer.

  • RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine

    The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Stelis Biopharma Pvt. Ltd., the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce, and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against coronavirus sufficient to vaccinate 100 million people. The agreement between RDIF and Stelis Biopharma was reached under the aegis of Enso Healthcare LLP (part of Enso Group), RDIF's coordination partner for sourcing Sputnik V vaccines in India.

  • Ultrasound has potential to damage coronaviruses : Study finds

    The coronavirus’ structure is an all-too-familiar image, with its densely packed surface receptors resembling a thorny crown. These spike-like proteins latch onto healthy cells and trigger the invasion of viral RNA. While the virus’ geometry and infection strategy is generally understood, little is known about its physical integrity.

  • Vaccines alone may not be enough to end pandemic

    Even as vaccines are becoming more readily available in the U.S., protecting against the asymptomatic and pre-symptomatic spread of the virus (SARS-CoV-2) that causes COVID-19 is key to ending the pandemic, say two Georgetown infectious disease experts.

  • MHRA response to the precautionary suspensions of COVID-19 Vaccine AstraZeneca

    It has not been confirmed that the reports of blood clots were caused by the AstraZeneca COVID-19 vaccine. People should still go and get their COVID-19 vaccine when asked to do so.

    Dr Phil Bryan, MHRA Vaccines Safety Lead said:
    The benefits of the vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, far outweigh the risks of side effects. People should go and get their COVID-19 vaccine when asked to do so

  • New class of substances for redox reactions

    Redox reactions play an important role in our everyday life. In these reactions, one compound releases electrons and is oxidized, while another accepts electrons and is reduced. Such redox reactions are exploited by living organisms, for example, to store energy.

  • Enzymatic danse macabre of lung cancer

    A chromatin-regulating enzyme has been shown by in-depth interdisciplinary investigations to be a key driver of a common type of lung cancer. Drugs that target the enzyme could improve treatment and survival rates for this particular cancer.

  • Amalaki Rasayana is effective in cardiac hypertrophy, says Research

    Using the integrated approach of cheminformatics and network systems biology, Researchers from IIT Guwahati investigated Amalaki Rasayana (AR), an Ayurvedic rejuvenate for the treatment of cardiovascular diseases such as pressure-overload left ventricular cardiac hypertrophy (LVCH). The study has been published in the Nature Partnership Journal System Biology and Applications.

Subscribe to Pharma News